Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver‐Distributed Farnesoid X‐Receptor Agonist TERN‐101 in Healthy Volunteers

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease

(2020) F. Anthony Romero et al.   JOURNAL OF MEDICINAL CHEMISTRY

A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia

(2020) Maureen Sampson et al.   JAMA Cardiology

Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data

(2020) Rohit Loomba et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)

(2020) Stefano Fiorucci et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

SAT-341-MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects

(2019) Hubert Chen et al.   JOURNAL OF HEPATOLOGY

Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial

(2018) Dana Friedrich et al.   BMC GASTROENTEROLOGY

Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects

(2018) A. Ahmad et al.   JOURNAL OF HEPATOLOGY

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

(2018) Chris Estes et al.   JOURNAL OF HEPATOLOGY

FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver

(2018) Romeo Papazyan et al.   JOURNAL OF LIPID RESEARCH

Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

(2018) Zobair Younossi et al.   HEPATOLOGY

Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers

(2016) R. Pencek et al.   DIABETES OBESITY & METABOLISM

Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

(2015) Michael J. Genin et al.   JOURNAL OF MEDICINAL CHEMISTRY

The TGR5 receptor mediates bile acid–induced itch and analgesia

(2013) Farzad Alemi et al.   JOURNAL OF CLINICAL INVESTIGATION

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression

(2008) Kwang-Hoon Song et al.   HEPATOLOGY